Table 2.

Clonal mtDNA mutations identified in prostate cancer epithelium and benign stroma

Patient IDGleason scoreaGenebDNAcProteindPCE (%)eStroma (%)fBlood(%)g
23300B3+3ND513913T>CL526P50N.D.N.D.
22871B3+3ATPase69038T>CM171T50N.D.N.D.
23388H3+3None
23529W3+316SrRNA2107G>A100N.D.N.D.
23481P3+3None
19575Y3+3None
22951A3+3None
22949P3+3tRNAEE14724G>A50%N.D.N.D.
23127O3+3None
22904L3+3ND13982G>AA226T80%N.D.N.D.
Cytb15345T>CL200S70%N.D.N.D.
22880H3+3COXIII9942G>AD246N50%N.D.N.D.
23024K3+3None
23270S3+3None
22905A3+4None
23002C3+4None
19416E3+4Cytb14774insCFrameshift100%N.D.N.D.
22860F3+4D-loop523delAC100%N.D.N.D.
12S rRNA1282G>A80%N.D.N.D.
ND310320A>GI88V100%N.D.N.D.
23027B3+4COXI6131A>G60%N.D.N.D.
COXI6910C>T A336V80%N.D.N.D.
22870S3+4D-loop16171G>A60%N.D.N.D.
22975M3+4None
23201A3+4ND310264T>CI69T70%N.D.N.D.
23028W3+4None
23266N3+4None
23312L3+4None
23159R3+4None
22896V3+4None
23204T3+4None
23378W3+4ND13643G>AV113I60N.D.N.D.
23390H3+4None
23569O3+4ND310228T>CL57S100N.D.N.D.
23036D4+3ND513525G>AE397K100N.D.60
23171D4+3D-loop313del CCCCGCTTCT50N.D.50
ND24752T>CS95P100N.D.50
22962M4+3D-loop309delC50N.D.N.D.
22959H4+3None
23253G4+3Cytb15750T>CL335P100N.D.N.D.
22927H4+3D-loop251G>A70N.D.N.D.
Cytb14846G>AG34S100N.D.N.D.
22888L4+3None
23168H4+3ND512473T>CI46T80%N.D.N.D.
23183S4+5ND513480G>AG382stop80%N.D.N.D.
Cytb14798T>CF18L50%N.D.N.D.
23570B3+3ND411256A>GY166CN.D.60N.D.
23461T4+3None
  • aTumors were graded based on the Gleason Grading System, with the first number indicating the grade of the majority (>50%) of the tumor (on a scale from 1–5), and the second number signifying the grade of the minority (<50%, but >5%) of the tumor.

  • bThe region or gene in the mitochondrial genome where the mutation was detected by Sanger sequencing.

  • cThe mutation is indicated by the base position in mtDNA, followed by the type of change. A T to C substitution at position 1000 would be described as 1000T>C, where a deletion of a G at position 500 would be 500delG.

  • dAmino acid change resulting from the mutation, indicated by the original amino acid followed by the position of the residue, and then the resulting amino acid.

  • ePrevalence of mutation in LCM cancerous prostate tissue as a percentage, based on Sanger sequencing chromatogram reads. N.D. indicates that the mutation was not detectable via Sanger sequencing.

  • fPrevalence of mutation in LCM benign prostate stroma as a percentage, based on Sanger sequencing chromatogram reads.

  • gPrevalence of mutation in blood DNA as a percentage, based on Sanger sequencing chromatogram reads.